BirchBioMed ^{Filed Terms, Nasdaq: BRBM}

The Company is a clinical stage biopharmaceutical company focused on developing treatments for scarring (fibrosis, i.e., the overproduction and insufficient breakdown (or remodeling) of ECM proteins, predominantly collagen and fibronectin, within an organ) and related skin disorders; certain autoimmune diseases (diseases consisting of immune responses of an organism against its own cells and tissues); and organ fibrosis. We hold the exclusive, worldwide, non-perpetual pharmaceutical licenses from the University of British Columbia (“UBC”) for two scientific technologies, FS1/FS2 and AI-001. Based on preclinical studies and clinical trials we have conducted to date, we believe these technologies hold the potential for significant medical breakthroughs in the treatment of certain debilitating conditions/disorders in need of novel, better solutions. Our main, strategic focus is developing our lead product candidate, FS2, as a prescription medicine (“Rx drug”) for the treatment of severe diseases with highly unmet medical needs, including the treatment of burns and organ fibrosis. We are also developing the use of AI-001 as an Rx drug for the treatment of patients with type 1 diabetes (“T1D”), a lifelong autoimmune disease resulting in the destruction of pancreatic islet cells responsible for producing insulin, and Alopecia Areata (“AA”), autoimmune hair loss that causes patchy to complete hair loss.